Johnson & Johnson announced the launch of Evusheld injection in China.

GoldenOctober2024

On April 12, Jin10 reported that Johnson & Johnson announced the official launch of its innovative lung cancer treatment drug Ruko (Avelumab injection) in China. Ruko is administered in combination with carboplatin and pemetrexed and is indicated for first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer confirmed to carry epidermal growth factor receptor (EGFR) exon 20 insertion mutations.

View Original
Disclaimer: The information on this page may come from third parties and does not represent the views or opinions of Gate. The content displayed on this page is for reference only and does not constitute any financial, investment, or legal advice. Gate does not guarantee the accuracy or completeness of the information and shall not be liable for any losses arising from the use of this information. Virtual asset investments carry high risks and are subject to significant price volatility. You may lose all of your invested principal. Please fully understand the relevant risks and make prudent decisions based on your own financial situation and risk tolerance. For details, please refer to Disclaimer.
Comment
0/400
No comments